Eaton’s Vehicle Group Partners With Ballard Fuel Cell Systems and National Renewable Energy Laboratory to Develop Heavy-Duty Truck Fuel Cell Technology
Power management company Eaton today announced its Vehicle Group has partnered with leading fuel system manufacturer Ballard Fuel Cell Systems, and the Department of Energy’s National Renewable Energy Laboratory (NREL), to develop heavy-duty truck fuel cell technology. The partnership is the result of a grant Eaton’s Vehicle Group received from the U.S. Department of Energy to develop highly efficient hydrogen fuel cells capable of powering heavy-duty machinery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005019/en/
Eaton’s TVS technology to provide precise airflow for hydrogen fuel cells. (Photo: Business Wire)
The new fuel cell technology will leverage Eaton’s Twin Vortices Series (TVS) technology to improve fuel efficiency. This marks another important step in Eaton’s commitment to decarbonizing the transportation sector, building on the company’s more than two decades of investments and solutions that help to mitigate climate change.
“Our TVS supercharger technology provides fuel cell manufacturers with a precise amount of controlled air to increase power and efficiency,” said Karl Sievertsen, vice president and chief technology officer, Eaton’s Vehicle Group. “The efficiency of competitive fuel cells is lower because most hydrogen fuel cells use simple fans for air flow, which produces less pressure and is not controllable.”
Eaton will leverage its Corporate Research Labs in Golden, Colorado and Additive Manufacturing Center of Excellence in Southfield, Michigan to produce the technology, using cutting-edge power electronics and advanced 3D-printing. Eaton’s Vehicle Group will design and test a subscale, proof-of-concept system prototype utilizing its TVS technology that delivers a significant reduction in air system power consumption and fuel cell efficiency for heavy-duty truck applications.
Eaton’s TVS technology is ideal for harsh environments, as it can tolerate water, has operating maps with broad efficiency, and provides accurate air flow control in proportion to speed. These properties enable a water applicator to replace the humidifier to achieve higher operating pressure ratios and isentropic efficiencies.
“The innovation will be demonstrated in a laboratory setting and will become a springboard for U.S. advanced manufacturing capabilities and technology leadership,” Sievertsen added.
Eaton is a global leader in supercharger technology, having produced more than 9 million units over more than 30 years. All Eaton supercharger components are produced in-house utilizing state-of-the-art manufacturing processes and feature a patented rotor coating for improved efficiency. Eaton’s powder coating fills gaps between rotor lobes, tips and faces to mitigate air leakage and creates a near-zero clearance between components, resulting in optimal performance.
“We’re honored to be partnering with Ballard and the NREL to build this new, innovative technology that will address global climate change,” said Sievertsen. “Eaton has a long history of working with our industry counterparts and federal research organizations to create sustainable solutions, reduce our footprint and advance our vision of improving the quality of life and the environment.”
Learn more about Eaton’s 2030 Sustainability Goals.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005019/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom